P/E ratio for Madrigal Pharmaceuticals (MDGL)
P/E ratio as of May 2024 (TTM): -11.0
According to Madrigal Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.9946. At the end of 2022 the company had a P/E ratio of -16.8.
P/E ratio history for Madrigal Pharmaceuticals from 2007 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -16.8 | 190.43% |
| 2021 | -5.80 | -31.7% |
| 2020 | -8.49 | -49.2% |
| 2019 | -16.7 | -67.22% |
| 2018 | -51.0 | 41.14% |
| 2017 | -36.1 | 6766.18% |
| 2016 | -0.5263 | 42.81% |
| 2015 | -0.3685 | -87.62% |
| 2014 | -2.98 | -27.83% |
| 2013 | -4.13 | -51.51% |
| 2012 | -8.51 | 82.21% |
| 2011 | -4.67 | -29.03% |
| 2010 | -6.58 | -404.32% |
| 2009 | 2.16 | -196.81% |
| 2008 | -2.23 | 33.68% |
| 2007 | -1.67 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.65 | -57.72% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -90.95% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.